Is a complete PBLS research report available?

No complete published report is available for Parabilis Medicines, Inc. (PBLS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Parabilis Medicines, Inc. (PBLS)

NASDAQ: PBLS · USD

$31.8

+0.54 (+1.7%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-28 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first PBLS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	4.1B
Net income (ttm)	-209.7M
EPS (ttm)	-$67.1
Shares out	127.3M
Volume	222,285
Price target	$41.8	+31.2%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -209.7M
EPS (ttm): -$67.1
Market cap: 4.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All PBLS indicators

Market & fundamental data

Available fields

151

Groups with data

Currency

USD

Showing 151 of 151 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001657677
Company name	Parabilis Medicines, Inc.
Country	United States
Country code	US
Cusip	698955101
Employees	145
Employees Change	0%
Employees Change Percent	0
Enterprise value	$3.8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-07-12
Industry	Biotechnology
IPO Date	2026-06-10
Isin	US6989551014
Last refreshed	2026-07-28
Market cap	$4.1B
Market cap category	Mid-Cap
Price	$31.82
Price currency	USD
Sector	Healthcare
Sector PE	44.88
Sector PE Fwd	23.87
Sic	2834
Symbol	PBLS
Website	https://parabilismed.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-5.18%
EV Sales Forward	151.04x
FCF yield	-3.44%
P/B ratio	16.59x
PS Forward	162.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-209.7M
Net Income Growth Years	0%
Profit Per Employee	$-1.4M
ROCE	-46.09

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$384.2M
Cash	$329M
Current Assets	$332.1M
Current Liabilities	$54.2M
Debt	$53.1M
Debt Equity	$0.22
Equity	$244.2M
Interest Coverage	-107.5
Liabilities	$140M
Long Term Assets	$52.1M
Long Term Liabilities	$85.7M
Net Cash	$275.9M
Net Cash By Market Cap	$6.81
Net Debt Equity	$-1.13
Tangible Book Value	$-570.3M
Tangible Book Value Per Share	$-174

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.12
Net Working Capital	$-33.8M
Quick ratio	6.07
Working Capital	$277.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
All Time High	34.47
All Time High Change	-7.69%
All Time High Date	2026-06-11
All Time Low	24.51
All Time Low Change	29.82%
All Time Low Date	2026-06-15
ATR	2.71
Beta1y	-1.34
High	31.97
High52	34.47
High52 Date	2026-06-11
High52ch	-7.69%
Low	30.23
Low52	24.51
Low52 Date	2026-06-15
Low52ch	29.83%
Premarket Change Percent	-1.66
Premarket Price	$30.76
Premarket Volume	310
RSI	54.25
RSI Monthly	0
RSI Weekly	0
Sharpe ratio	0.42x
Sortino ratio	0.69
Tr1m	10.49%
Tr1w	16.51%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	5
Analyst Price Target Top	$41.75
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Operating Income	$-156.1M
Price target	$41.75
Price Target Change	$31.21
Price Target Change Top	$31.21

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	96,458,170%
Float Percent	75.75%
Net Borrowing	-6,845,000
Shares Insiders	0.09%
Shares Institutions	29.89%
Shares Out	127,337,446
Shares Qo Q	1.61%
Short Float	4.1%
Short Ratio	4.91
Short Shares	3.11

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-143.1M
Adjusted OCF	-142,528,000
Average Volume	464,625.15x
Bv Per Share	-174.1
CAPEX	$-601,000
Ch1m	10.49
Ch1w	16.51
Change	1.73%
Change From Open	1.56
Close	31.28
Days Gap	0.16
Depreciation Amortization	2,454,000
Dollar Volume	7,073,108.7
Earnings Date	2026-08-18
Earnings Time	bmo
EBIT	$-152.1M
EBITDA	$-149.6M
EPS	$-67.09
F Score	1
FCF	$-139.4M
FCF EV Yield	-3.69x
FCF Per Share	$-1.09
Financing CF	347,990,000
Fiscal Year End	December
Founded	2,015
Investing CF	32,700,000
Ipr	59.1
Iprfo	-4.59
Is Primary Listing	1
Is Spac	No
Last Report Date	2026-03-31
Last Split Type	Never
Ma20	29.93
Ma20ch	6.32%
Net CF	241,931,000
Next Earnings Date	2026-08-18
Open	31.33
Position In Range	91.38
Post Close	31.82
Postmarket Change Percent	0.06
Postmarket Price	$31.84
Ppne	43,933,000
Pre Close	31.28
Price Date	2026-07-27
Relative Volume	0.48x
Share Based Comp	3,769,000
Us State	Massachusetts
Volume	222,285

Parabilis Medicines, Inc. (PBLS)

Coverage state: Market snapshot only — no published research

Generate the first PBLS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · PBLS

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All PBLS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on PBLS

Frequently asked questions